PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: Frost & Sullivan

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Novel Drug Delivery Systems and Biologic Based Drugs Significantly Impact the U.S. Pharma Packaging - New analysis from Frost & Sullivan, U.S. Pharmaceutical Packaging Markets, reveals that revenues in these markets totaled $2,610 million in 2004 and can reach $3,338 million in 2011.
Novel Drug Delivery Systems and Biologic Based Drugs Significantly Impact the U.S. Pharma Packaging

 

NewswireToday - /newswire/ - Palo Alto, CA, United States, 2005/09/30 - New analysis from Frost & Sullivan, U.S. Pharmaceutical Packaging Markets, reveals that revenues in these markets totaled $2,610 million in 2004 and can reach $3,338 million in 2011..

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Drug delivery systems such as nasal spray, inhalers, transdermal patches, and oral ingestion redefine the U.S. pharmaceutical packaging markets. In addition, biologic based drugs and quick dissolving tablets increase the need for high barrier packages. The ease of use and convenience drives the shift from vials and ampules to prefilled syringes.

Nasal sprays and inhalers are likely to contribute to almost one-fourth of the revenue growth in the near future.

New analysis from Frost & Sullivan (chemicals.frost.com), U.S. Pharmaceutical Packaging Markets, reveals that revenues in these markets totaled $2,610 million in 2004 and can reach $3,338 million in 2011.

If you are interested in a virtual brochure, which provides manufacturers, end users, and other industry participants an overview of the latest analysis of the U.S. Pharmaceutical Packaging Markets, then send an e-mail to Trisha Bradley, Corporate Communications, at trisha.bradley[.]frost.com, with your full name, company name, title, telephone number, fax number, and e-mail address. Upon receipt of the above information, an overview will be sent to you by e-mail.

The role of pharmaceutical packaging shifts from a passive to an active one, thus becoming a critical component of drug delivery. There is an increased shift to high barrier and patient compliant packages.

“These new drug delivery systems are non-invasive and lead to better patient compliance,” points out Frost & Sullivan Research Analyst Balaji Capaloor. “Pharmaceutical packaging has become vital in the initial drug developmental stages of the pharmaceutical process.”

Particularly, biologics-based drugs – that are very sensitive to moisture, oxygen, and light – specifically require high barrier packages. Due to this requirement and focus on patient compliance, the share of blister packages increases.

“The overall development of the pharmaceutical packaging markets is buoyed by an increase in the acquisitions of existing companies by new entrants,” elaborates Capaloor.

Further, increasing prescription scripts, resulting in growth in the unit pharmaceutical sales, leads to higher demand for pharmaceutical packages.

In this scenario, the U.S. pharmaceutical manufacturers and converters concentrate on down gauging as well as reducing package thickness and raw material consumption without compromising on the product quality and by improving the processes and technologies implemented.

Cost reduction gains greater importance among pharmaceutical companies as there is a drop in the number of expected blockbuster drugs in the pipeline and many of drugs are going off patent.

Further, with the rise in the aging population, there is a greater demand for packages that are simultaneously convenient for elders to handle and are child-resistant.

Pharmaceutical manufacturers become involved in the design process to devise means to curtail the damages during transit in case of mail order and Internet pharmacies. They adopt innovative designs to make their products attractive. Pharmaceutical companies have started to look at implementation radio frequency identification (RFID) tags in packages to overcome counterfeiting and in addition for tracking and managing inventory across the supply chain.

Increasing consumer awareness of diseases, diagnosis, and treatment, as well as a subsequent rise in drug consumption helps pharmaceutical packaging evolve as a channel to promote drugs, where the efficiency of the drugs depend on their packaging.

The U.S. Pharmaceutical Packaging Markets, a part of the Plastics and Polymers subscription, provides an overview and outlook for the pharmaceutical packagers in the U.S. markets. It segments the markets into containers, tubes, closures, blister packages, pouches, vials and ampules, intravenous (IV) containers, prefilled syringes and inhalers, and nasal sprays. The study enables the manufacturers of these products to design strategies and position their products to benefit from the changing markets and obtain maximum return on investments. Analyst interviews and executive briefings are available to the press.

Frost & Sullivan, a global growth consulting company, has been partnering with clients to support the development of innovative strategies for more than 40 years. The company's industry expertise integrates growth consulting, growth partnership services, and corporate management training to identify and develop opportunities. Frost & Sullivan serves an extensive clientele that includes Global 1000 companies, emerging companies, and the investment community by providing comprehensive industry coverage that reflects a unique global perspective and combines ongoing analysis of markets, technologies, econometrics, and demographics.

U.S. Pharmaceutical Packaging Markets
F350-39

Contact:
Trisha Bradley
Corporate Communications – North America
P: 210.247.3870
F: 210.348.1003
E: trisha.bradley[.]frost.com

Katja Feick
Corporate Communications – Europe
P: +44 (0) 20 7915 7856
F: +44 (0) 20 7730 3343
E: katja.feick[.]frost.com

Donna Jeremiah
Corporate Communications – Asia Pacific
P: +603 6304 5832
F: +603 6201 7402
E: djeremiah[.]frost.com

Keywords in this release: pharmaceutical packaging, United States, transdermal patches, oral ingestion, containers, tubes, closures, blister packages, pouches, vials and ampules, intravenous containers, IV, prefilled syringes, prefilled inhalers, nasal sprays, radio frequency identification, RFID research, information, market, trends, technology, service, forecast, market share

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: Frost & Sullivan

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Novel Drug Delivery Systems and Biologic Based Drugs Significantly Impact the U.S. Pharma Packaging

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: Trisha Bradley 
210.247.3870 trisha.bradley[.]frost.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Frost & Sullivan securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Frost & Sullivan / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

MDxHealth and Exact Sciences Sign Collaboration Agreement
BD Advances Efforts to Combat Antimicrobial Resistance with Enhanced Diagnostic Solution Offering
First European Patients Treated with DC Bead LUMI™ Radiopaque Drug-Eluting Beads
FDA Approves Genentech’s Lucentis (Ranibizumab Injection) for Diabetic Retinopathy
Biopharmaceutical Analytical Instrumentation Market Garners Strong Opportunities from Double-digit Growth in Biosimilars Finds Frost & Sullivan
BD Completes Acquisition of Caesarea Medical Electronics
MDxHealth and Ghent University Ink Licensing and Collaboration Agreements to Develop Cancer Biomarker Visualization Technology
Ipsen Completes Acquisition of ONIVYDE® (irinotecan liposome injection) and Additional Oncology Assets from Merrimack Pharmaceuticals
FDA Grants Breakthrough Therapy Designation for Rituxan® (Rituximab) in Pemphigus Vulgaris
MDxHealth Signs Agreement with Lab21 to Make SelectMDx Liquid Biopsy Test Available in the United Kingdom
Greenphire Drives Global Site Adoption of Clinical Trial Payment Solutions
Ipsen Announces MHRA Approval of New Indication for Decapeptyl® for the Treatment of Pre-menopausal Women with Early Stage Breast Cancer
SelectMDx Chosen by Michigan Medicine as Pre-biopsy Diagnostic Tool in Groundbreaking US Prostate Cancer Risk Clinic
BTG Announces CE Mark Certification for DC Bead LUMI™ - The First Commercially Available Radiopaque Drug-Eluting Bead
Sartorius to Acquire Real-time Live-cell Analysis Pioneer and Leader Essen BioScience

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  NAKIVO, Inc.

Visit  JobsWare.com





 
  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)